Authors: Pratibha Anand 1, Vincent P Stahel 2 Abstract The novel coronavirus disease 2019 (COVID-19) has infected more than 100 million people globally within the first year of the pandemic. With a death toll surpassing 500,000 in the United States alone, containing the pandemic is predicated on achieving herd immunity on a global scale. This implies that at […]
Authors: Musha Chen, Yue Yuan, Yiguo Zhou, Zhaomin Deng, Jin Zhao, Fengling Feng, Huachun Zou & Caijun Sun Background Various modalities of vaccines against coronavirus disease 2019 (COVID-19), based on different platforms and immunization procedures, have been successively approved for marketing worldwide. A comprehensive review for clinical trials assessing the safety of COVID-19 vaccines is urgently needed to make an accurate judgment for […]
Authors: Anne M. Hause, PhD1; Julianne Gee, MPH1; James Baggs, PhD1; Winston E. Abara, MD1; Paige Marquez, MSPH1; Deborah Thompson, MD2; John R. Su, MD, PhD1; Charles Licata, PhD1; Hannah G. Rosenblum, MD1,3; Tanya R. Myers, PhD1; Tom T. Shimabukuro, MD1; David K. Shay, MD1 Summary What is already known about this topic? In preauthorization […]
Authors: Project director: Nikhil K. Mull, MD (CEP), Lead analyst: Matthew D. Mitchell, PhD (CEP), Clinical review: Patrick J. Brennan, MD. (CMO) EVIDENCE SUMMARY: 1. There are no specific guidelines for use of messenger RNA (mRNA) vaccines or contraindications to mRNA vaccines.2. No large trials of any mRNA vaccine have been completed yet.3. The only […]
Authors: C. Ferreras1†, B. Pascual-Miguel1†, C. Mestre-Durán1, A. Navarro-Zapata1, L. Clares-Villa1, C. Martín-Cortázar1, R. De Paz2, A. Marcos2, J. L. Vicario3, A. Balas3, F. García-Sánchez3, C. Eguizabal4,5, C. Solano6, M. Mora-Rillo7, B. Soria8,9 and A. Pérez-Martínez1,10,11* Syndrome coronavirus 2 (SARS-CoV-2) pandemic is causing a second outbreak significantly delaying the hope for the virus’ complete eradication. In the absence of effective vaccines, we need effective treatments with low adverse effects that can […]
Authors: Christina Aungst, PharmD Key takeaways: People who were sick with COVID-19 and recovered might have long-term immunity that lasts for months or years. We don’t know how long vaccine immunity lasts yet, but it is much safer to gain immunity from the vaccine than from getting COVID-19. Experts believe the vaccine will still work […]
Authors: Larissa E van Eijk, 1 , † Mathijs Binkhorst, 2 , † Arno R Bourgonje, 3 , ‡ Annette K Offringa, 4 , ‡ Douwe J Mulder, 5 Eelke M Bos, 6 Nikola Kolundzic, 7 , 8 Amaal E Abdulle, 5 Peter HJ van der Voort, 9 Marcel GM Olde Rikkert, 10 Johannes G van der Hoeven, 11 Wilfred FA den Dunnen, 1 Jan‐Luuk Hillebrands, 1 , § and Harry van Goor 1 , § Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), continues […]
https://www.openvaers.com/covid-data Important Things To Know About VAERS VAERS is an early warning system used to monitor adverse events that happen after vaccination. VAERS is the frontline system of a comprehensive vaccine safety monitoring program in the United States. It is one of several systems CDC and the US Food and Drug Administration (FDA) use to help ensure all […]
Authors: Williamson, Jack A. Hassard, Ecco Staller, Brian Hanley, Michael Osborn, Mauro Giacca, Andrew D. Davidson, David A. Matthews & Wendy S. Barclay SARS-CoV-2 entry requires sequential cleavage of the spike glycoprotein at the S1/S2 and the S2ʹ cleavage sites to mediate membrane fusion. SARS-CoV-2 has a polybasic insertion (PRRAR) at the S1/S2 cleavage site that can be cleaved by furin. Using lentiviral pseudotypes […]
Author: Dr. Charles Hoffe in a Coronavirus, that spike protein becomes part of the viral capsule. In other words, the cell wall around the virus, called the viral capsule. But it’s not in the virus. It’s in your cells. So it therefore becomes part of the cell wall of your vascular endothelium. Which means that […]